Imprimis NJOF, LLC, Ledgewood, NJ

Is Imprimis NJOF, LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Imprimis NJOF, LLC in Ledgewood, NJ, first registered Nov 12, 2016 and most recently registered Nov 26, 2025.

Does Imprimis NJOF, LLC hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301011284 for Imprimis NJOF LLC, Ledgewood, NJ, status Active, as of Nov 10, 2026.

Has Imprimis NJOF, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 7, 2019) for Imprimis NJOF, LLC. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists “Through a disciplinary action of the Board, the license is voluntarily surrendered, subject to terms and conditions in the decision” dated Feb 1, 2026, case AC 7456 on nonresident license NSF 133.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Imprimis NJOF, LLC
Location
Ledgewood, NJ
Type as FDA labels it
503B
FDA 503B list
Listed as Imprimis NJOF, LLC
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
Aug 18, 2026
FDA Data Dashboard inspections
3 inspections: 3 OAI; 4 published Form 483s
Form 483 text on this page
1 Form 483, 11 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Imprimis NJOF, LLC, a 503B facility, with 4 dated actions.

Document
Aug 18, 2026Form 483483 Issued 08/18/2026fda.gov
Apr 3, 2024Form 483483 Issued 04/03/2024FDA copy (archived)
Jan 29, 2021Form 483483 Issued 01/29/2021FDA copy (archived)
Jun 7, 2019Warning letterWarning Letter (06/07/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Imprimis NJOF, LLC, Ledgewood, NJ (FEI number 3013024146), matched to this page by exact name, city and state. It lists 3 inspections: 3 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 3, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30130241461231238
Jan 29, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30130241461135834
Jul 10, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30130241461024871

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 11 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 24, 2017: 11 observations

Firm on the cover
lmprimis NJOF, LLC, 1705 Roule 46 West, suite 68, Outsourcing Facili1y Ledgewood, NJ 07852-9720
FEI number
3013024146
FDA district office on the cover
10 Waterview Blvd., 3"'. Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

a. The following batches of ophthalmic sterile drug products that were manufactured, released, and distributed to the market were not environmentally monitored for non-viable and viable airborne particles counts. During these manufacturing operations the <Redacted B4> and the <Redacted B4> were not operational. Additionally, the media fills that were produced to support .the sterile manufacturing operations of the below lots were also not environmentally monitored for non-viable and viable particle counts.

Specifically,

Product

Lot Number

Prednisolone (l.0%) / Garifloxacin (0.5%) / Nepafenac (0.1 %)(PGN) -Droppers

JAN007 and FEB002

Triamcinolone (l 5mg/mL)/Moxifloxacin HCI (l mglmL) (TM)-vials for injection

JAN008, JAN009, JAN010, JAN017, JAN0l8, JAN009, and JAN026.

Triamcinolone (15mg/mL)/Moxifloxacin HCI (I mg/mL)/ Vancomycin (IO mg/ml) (TMV)-vials for injection

JAN021, JAN022, JAN023, FEB006, FEB007, and FEB008

Media Fills

JANOOl, JAN002, JAN003, JAN004, JAN005, JAN006, and JAN025 ...

Read the full 483 (PDF on fda.gov)

Observation 2

. ... Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate ·validation of the sterilization process.

Specifically, the smoke study of the ISO 5 laminar air flow hood was either not provided or lacked critical activities to demonstrate that the HEPA filtered air supply can maintain aseptic conditions. For example:

a.

The initial visualization of the unidirectional air flow (smoke study) to support the sterile filling operations in the lSO 5 <Redacted B4> laminar air flow hood during January and February 2017 was not found or provided during the inspection.

b. The air flow pattern visualization (smoke study) conducted on <Redacte d B4> failed to include cri tical activities, such as product filling, manipulation and actions whe n the <R edacted B4> is present wi th <Redacted B4> operators in the laminar air flow hood. The smoke study was conduct ed with < Redacted B4> p resent without the <Redacted B4> that holds the bulk product while no pr

oduct filling occurred . This smoke study also failed to demonstrate a continued pattern of unidirectional ai r flow. The video lasted <Redacted B4>.

Observation 3

Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used.

Specifically, cleaning procedure EQU-UMR-NJR-007, Cleaning, Disinfection, and Decontamination of Clean Rooms and Equipment, fails to describe in sufficient detail the cleaning techniques and necessary steps to clean and disinfect the laminar air flow hood (ISO 5), used for filling sterile drug products. Additionally, this SOP also fails to describe the method used to clean various fixtures in the ISO 7 filling room such as the plastic curtain, doors, and piping located on the wall.

In addition, the effectiveness of the sanitization procedures have not been demonstrated through surface samples before and after cleaning and disinfection of the ISO 7 and laminar air flow hood (ISO 5) areas.

MPLEMENT. CORRECTIVE ACTIOll I» RESP()t.ISE TOAN OBSERVATION, YOU MAY OISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESEflTATIVE(S) OURJNG THE INSPECTION OR SUBMIT THIS INFORW. TION TO FDA AT Tl-IE A00R£SS ABOVE. IF YOU HAVE ANY OUESTIOllS, Pl.EASE CONTACT FDA AT THE PHONE NUMBER ANO AOORESS ABOVE.

OURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

Observation 4

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch bas been already distributed.

Specifically, thorough investigations for the following customer complaints were not conducted and corrective actions were not implemented or documented.

a.

On 04/04/2017, a consumer complaint reported the presence of black/grey particles in Triamcinolone (15 mg/mL)/Moxifloxacin HCI (1 mg/mL), lot numbers JAN026 and FEB011 Lot JAN026 was released and commercially distributed to approximately <Redacted B4> customers without environmental monitoring of non-viable and viable airborne particle counts during the filling operation because the <Redacted B4> and the <Redacted B4> were not operational. Lot FEBO I I was released and commercially distributed to approximately <Redacted B4> customers. The retain samples for both lots were not evaluated to determine if they were contaminated with particles. The investigation into Lot JAN026 was not extended to other batches that were also processed without non-viable and viable airborne particle monitoring. The black/grey particles were not analyzed by a laboratory to determine their identity. ...

Read the full 483 (PDF on fda.gov)

Observation 5

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically, there is no establisbed procedure that details how to conduct the <Redacted B4> test for Moxifloxacin 5 rng/mL (0.5%) Injectable as well as what equipment and materials are needed for the test. In addition, the gauge of the <Redacted B4> used to perform this <Redacted B4> test is not calibrated and there is no established <Redacted B4> calibration procedure.

Observation 6

Production personnel were not practicing good sanitation and health habits.

Specifically, on 04/26/2017, during the filling operation of Prednisolone (l.0%)/Gatifloxacin (0.$%)/Nepafenac (0.1 %} -Droppers lot APR024 we observed two occasions when the sterile operator's band passed a bag and a tray from the

ISO 7 to the ISO 5 area without spraying their gloved hands with sterile <Redacted B4>

Observation 7

Examination of a lot of a component, drug product container or closures liable to contamination with extraneous adulterant is deficiently examined against established specifications for such contamination.

Specifically, there is no assurance that the incoming plastic bottles sterilized by <Redacted B4> and used for filling the following finished drug products are free of <Redacted B4> residue. Neither Imprimis nor the bottle supplier perform testing or have documentation to show that they are free of residue.

Prednisolone (1.0%)/Gatifloxacin (0.5%)/Nepafenac (0.1%)-Droppers

Prednisolooe {I .0%)/Gatifloxacin (0.5%)-Droppers

Prednisolooe (1.0%)/Nepafenac (0.1%) -Droppers

MPLEMENT, CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY OISCUSS THE OBJECTION OR ACTIOI~ WITH THE FDA REPRESENTATIVE(S) OURJNG THE INSPECTION ORSUBl.'JT THIS IWFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS. PLEASE CONTACT FOAAT THE PHONE NUMBER ANO ADDRESS ABOVE.

(>U!~ING AN INSPECTION OF YOUR FIRM WE OBSERVED:

Observation 8

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Specifically, the following lots of API were used to manufacture sterile drug products without having a certificate of analysis from the supplier and their identification was not verified by conducting at least one test.

a. Vancomycin Hydrochloride, lot number (15) @JJ used to manufacture the validation batch Triamcinolone (15 mg/mL)/Moxifloxacin HCL ( 1 mglmL)/Vancomycin (l 0 rng/mL) Injection lot# JAN02 l. This finished sterile drug product was commercially distributed in 02/2017.

b. Vancomycin Hydrochloride, lot number <Redacted B4> used for the manufacture of Triamcinolone (15 mg/mL)/Moxifloxacin HCL (1 mg/mL)/Vancomycin (10 mg/ml) lot numbers JAN022, JAN023, FEB006, FEB007, and FEB008. These finished drug products were commercially distributed throughout February and March 2017.

Observation 9

Adequate lab facilities for testing and approval or rejection of drug products are not available to the quality control unit.

Specifically, contract laboratory facilities have not been audited or qualified to determine their adequacy for testing of drug products and media fills:

a.

There are no agreements or procedures in place with any of the contract laboratories (chemical and microbiological) to inform Imprirnis about issues that occur during laboratory testing such as deviations and out of specification (OOS) results.

b. There is no assurance that the contract laboratory used for the sterility and endotoxin testing for Triamcinolone (15 mg/mL)/Moxifloxacin HCI (1 mg/mL)/Vancomycin ( 10 mg/mL) Injectable lot numbers JAN021 and FEBOI 4, and endotoxin testing for Prednisolone (1.0%)/Gatifloxacin (0.5%)/Nepafenac (O.l %) lot number APR024 has the capability to perform the required testing in an accurate, precise, and reliable way.

c. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, the number of finished product samples taken per batch is dictated by the contract laboratory. There is no Imprimis procedure or sampling plan that is used to determine if a representative quantity of drug product was taken. The following sterile drug products were involved in a customer complaint where a patient developed endophthalmitis and Staphylococcus epidermidis was identified by a hospital clinical laboratory.

a. Triamcinolone (15 mg/mL)/Moxifloxacin HCl (1 mg/mL) Injectable lot JANOI9, commercially released

to the market to approximately <R edacted B4> customers during 2017 bad a batch size of approx i m ately <Re dacted B4> vials. The sample size for chemical analysis (p otency) was <Redacted B4> vials and the samp le size for sterility a nd endotoxin testing was <Redacted B4> vials <Redacted B4> was analyzed for endotoxin testing.

b. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Establishment of the reliability of the container closure supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.

Specifically, the suppliers of the following container closure systems have not been qualified or audited. Jn addition, there has not been any testing conducted of these containers and closures to demonstrate reliability of the supplier's COA.

a. The supplier that provides the 2 ml amber vials and 13 mm grey stoppers

b. The supplier that provides the plastic bottles and < Redacted B 4>

OBSERVATJON 12

The quality control unit lacks the responsibility and authority to approve or reject all packaging material.

Specifically, the quality unit failed to identify discrepancies in the sterilization method of the <Redacted B4> (the <Redacted B4>, lot numbers <Redacted B4> and <Redacted B4> used for sterile drug products containing Prednisolone. The label indicates sterilization by <Redacted B4>; however, during the inspection, the supplier stated that the sterilization method was actually <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301011284PharmacyImprimis NJOF LLCLedgewood, NJActive

FDA’s 503B list

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.